Living Cell Technologies Received JDRF Grant for DIABECELL® NZ Clinical Trial
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on April 27, 2010
DIABECELL® is Living Cell Technologies' treatment designed for people with insulin-dependent diabetes. Now, LCT has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL® in New Zealand from the Juvenile Diabetes Research Foundation International (JDRF).
DIABECELL® is composed of encapsulated porcine insulin-producing cells (islets) that are implanted into the abdomen of patients using a simple laparoscopic procedure and works by self-regulating and efficiently secreting insulin in the patient's body.
The JDRF grant will contribute to the second portion of the Phase II trial, which will test the safety and efficacy of DIABECELL® given in higher amounts in patients with type 1 diabetes. The first four patients have already received implants and early observations show clinical benefit without remarkable adverse events to date.
Tags: DIABECELL®, JDRF, Living Cell Technologies diabecell living+cell cell+technologies
Vote for Living Cell Technologies Received JDRF Grant for DIABECELL® NZ Clinical Trial:
|
Rating: 8.40 out of 5 vote(s) cast.
|
Response from:
Tony Gray
(05/05/10 3:36pm)
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Follow us on Twitter! |
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
My daughter has completed a degree in Bio medical science and is currently completing Bachelor of Medicine and surgery in Sydney, Australia. She is 22 years old and has suffered type 1 diabetes since she was 9 years old.
At this stage in her life she is struggling with her management of the disease and particularly concerned at unexpected and dramatic highs and lows with her blood sugars.
We would like to know more about what Living cell technology has to offer with a possible view to Hannah participating in future clinical trialling.
Can you please advise what would be required.
with thanks
Tony Gray.
email: bluegray@xtra.co.nz